Q3 FY2026 · ended Sep 30, 2026 · Revenue $656.40M, +0.5% YoY · Filed Nov 4, 2026
Bio-Rad Laboratories, Inc. (BIO) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $656.4 million and net income of $458.6 million. Free cash flow was $65.2 million. As of Sep 30, 2026 it held $7.9 billion in cash and investments and $1.4 billion in total debt.
Revenue
$656.40M
+0.5% vs year-ago quarter
Net income
$458.60M
+234.1% vs year-ago quarter
Operating cash flow
$96.40M
-20.3% vs year-ago quarter
Free cash flow
$65.20M
-26.9% vs year-ago quarter
EPS
$17.02
+234.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
27.67M
Net cash
$6.57B
Q3 FY2026
Operating margin
-2.4%
TTM
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BIO (NYSE), BIO-B (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hercules, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 12208
- Former names
- BIO RAD LABORATORIES INC (until Jun 18, 2018)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bruker Corp BRKR
- 10x Genomics, Inc. TXG
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $656.4M | $651.0M | $592.1M | $693.2M | $653.0M |
| Operating income | -$49.7M | $72.6M | $34.1M | -$118.9M | $65.3M |
| Net income | $458.6M | $371.4M | -$527.1M | $720.0M | -$341.9M |
| Diluted EPS | $17.02 | $13.85 | -$19.55 | $26.65 | -$12.70 |
| Operating cash flow | $96.4M | $98.7M | $108.1M | $164.9M | $120.9M |
| Free cash flow | $65.2M | $66.7M | $78.1M | $119.1M | $89.2M |
| Total assets | $10.8B | $10.3B | $9.8B | $10.6B | $9.7B |
| Total liabilities | $3.2B | $3.1B | $2.9B | $3.1B | $3.0B |
| Stockholders' equity | $7.6B | $7.2B | $6.9B | $7.5B | $6.7B |
| Cash and investments | $7.9B | $7.3B | $6.9B | $7.6B | $6.5B |
| Total debt | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure
|
Aug 4, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 30, 2026 | Apr 30, 2026 |
All 1000 Bio-Rad Laboratories, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.